In some countries outside the U.S., an expanded access program is available for pembrolizumab, Merck’s anti-PD-1 antibody, for eligible patients with advanced melanoma who have been previously treated with ipilimumab and, if indicated, a BRAF inhibitor. Information is available on www.clinicaltrials.gov.
The pembrolizumab Expanded Access Program for advanced melanoma is administered by a partner company, Idis. Physicians outside the U.S. can reach Idis at +44 (0)1932 824 123 or at email@example.com.
Only physicians can enroll patients in the EAP. Patients should work through their physician to determine if they are eligible to enroll in the EAP.
The pembrolizumab Expanded Access Program for advanced melanoma is no longer enrolling new patients in the U.S. since the medicine is now approved by the U.S. Food and Drug Administration (marketed under the brand name KEYTRUDA®). If you have questions about the transition from the EAP, please talk to your physician or call the Merck Access Program care team at 1-855-257-3932.